| 2025-12-22 |
详情>>
股本变动：
变动后总股本9219.78万股
|
| 2025-09-17 |
详情>>
业绩披露：
2025年中报每股收益-0.25欧元,归母净利润-2134.4万欧元,同比去年增长13.81%
|
| 2025-04-30 |
详情>>
业绩披露：
2024年年报每股收益-0.61欧元,归母净利润-4947.1万欧元,同比去年增长-553.51%
|
| 2024-11-13 |
财报披露：
美东时间 2024-11-13 盘前发布财报
|
| 2024-09-12 |
详情>>
业绩披露：
2024年中报每股收益-0.31欧元,归母净利润-2476.4万欧元,同比去年增长-1541.44%
|
| 2024-04-15 |
股东大会：
将于2024-05-23召开股东大会
|
| 2024-04-04 |
详情>>
业绩披露：
2023年年报每股收益-0.09欧元,归母净利润-757万欧元,同比去年增长86.97%
|
| 2023-09-14 |
详情>>
业绩披露：
2023年中报每股收益0.02欧元,归母净利润171.80万欧元,同比去年增长-72.74%
|
| 2023-04-06 |
详情>>
业绩披露：
2022年年报每股收益-0.73欧元,归母净利润-5810.3万欧元,同比去年增长-10.02%
|
| 2023-04-06 |
详情>>
业绩披露：
2020年年报每股收益-0.81欧元,归母净利润-6398.4万欧元,同比去年增长-208.22%
|
| 2022-09-15 |
详情>>
业绩披露：
2022年中报每股收益0.08欧元,归母净利润630.30万欧元,同比去年增长126.57%
|
| 2022-04-08 |
股东大会：
将于2022-05-20召开股东大会
|
| 2022-04-04 |
详情>>
业绩披露：
2019年年报每股收益-0.31欧元,归母净利润-2075.9万欧元,同比去年增长-780.85%
|
| 2022-04-04 |
详情>>
业绩披露：
2021年年报每股收益-0.66欧元,归母净利润-5280.9万欧元,同比去年增长17.47%
|
| 2021-09-17 |
复牌提示：
2021-09-17 09:46:05 停牌，复牌日期 2021-09-17 09:51:05
|
| 2021-09-15 |
详情>>
业绩披露：
2021年中报每股收益-0.3欧元,归母净利润-2371.9万欧元,同比去年增长-129.52%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-21 |
股东大会：
将于2021-05-28召开股东大会
会议内容 ▼▲
- 1.Approval of the annual financial statements for the 2020 fiscal year
2.Approval of the consolidated financial statements for the 2020 fiscal year
3.Allocation of earnings for the fiscal year
4.Related-party transactions entered into with the Centre Léon Bérard and Jean-Yves Blay
5.Related-party transaction entered into with Pascale Boissel
6.Related-party transaction entered into with Novo Nordisk A/S
7.Related-party transaction entered into with Bpifrance Financement
8.Renewal of Hervé Brailly as member of the Supervisory Board
9.Renewal of Gilles Brisson as member of the Supervisory Board
10.Renewal of Irina Staatz Granzer as member of the Supervisory Board
11.Renewal of Véronique Chabernaud as member of the Supervisory Board
12.Renewal of Patrick Langlois as member of the Supervisory Board
13.Renewal of Bpifrance Participations as member of the Supervisory Board
14.Renewal of Jean-Yves Blay as member of the Supervisory Board15.Renewal of Olivier Martinez as observer of the Supervisory Board
16.Determination of the compensation referred to in article L.225-83 of the French Commercial Code to be allocated to members of the Supervisory Board
17.Approval of the general principles of the compensation policy of the corporate officers (mandataires sociaux) for the 2021 fiscal year
18.Approval of the compensation policy of the Chairman of the Executive Board for the 2021 fiscal year
19.Approval of the compensation policy of the Executive Board members (except the Chairman of the Executive Board) for the 2021 fiscal year
20.Approval of the compensation policy of the Chairman of the Supervisory Board for the 2021 fiscal year
21.Approval of the compensation policy of the Supervisory Board members (except the Chairman of the Supervisory Board) for the 2021 fiscal year
22.Approval of the various components of overall compensation and benefits granted for the fiscal year ended 31 December 2020 to the corporate officers (mandataires sociaux)
23.Approval of the components of overall compensation and benefits granted for the fiscal year ended 31 December 2020 to the Chairman of the Executive Board
24.Approval of the components of overall compensation and benefits granted for the fiscal year ended 31 December 2020 to the Executive Board members (except the Chairman of the Executive Board)
25.Approval of the components of overall compensation and benefits granted for the fiscal year ended 31 December 2020 to the Chairman of the Supervisory Board
26.Authorization for the Company’s purchase of its own shares
27.Authorization granted to the Executive Board to allocate share subscription and/or share purchase options for the benefit of employees of the subsidiary of the Company, Innate Pharma Inc.
28.Authorization granted to the Executive Board to allocate existing or new free shares for the benefit of employed members of the Executive Committee, employed senior executives and/or corporate officers of the Company or its subsidiaries as part of their variable annual compensation
29.Authorization granted to the Executive Board to allocate existing or new free shares on the basis of the performance criteria for the benefit of executive officers, employed members of the Executive Committee, employed senior executives and/or corporate officers of the Company or its subsidiaries
30.Authorization granted to the Executive Board to allocate existing or new free shares on the basis of the performance criteria for the benefit of employees of the Company or its subsidiaries
31.Delegation of authority to the Executive Board for the purpose of issuing ordinary shares and/or securities giving access to the share capital of the Company for the benefit of the members of a company savings plan
32.Delegation of power granted to the Executive Board for the purpose of cancelling all or part of the treasury shares of the Company, acquired pursuant to the authorization to repurchase shares
33.Amendment of the Articles of Association
34.Powers for formalities
|
| 2020-04-14 |
股东大会：
将于2020-05-19召开股东大会
会议内容 ▼▲
- Resolutions to be submitted to the ordinary shareholder’s meeting
1.Approval of the annual financial statements for the 2019 fiscal year
2.Approval of the consolidated financial statements for the 2019 fiscal year
3.Allocation of earnings for the fiscal year
4.Related-party transactions
5.Appointment of Pascale Boissel as member of the Supervisory Board
6.Renewal of Olivier Martinez as observer of the Supervisory Board
7.Determination of the compensation referred to in article L.225-83 of the French Commercial Code to be allocated to members of the Supervisory Board
8.Approval of the general principles of the compensation policy of the corporate officers (mandataires sociaux) for the 2020 fiscal year
9.Approval of the compensation policy of the Chairman of the Executive Board for the 2020 fiscal year
10.Approval of the compensation policy of the Executive Board members (except the Chairman of the Executive Board) for the 2020 fiscal year
11.Approval of the compensation policy of the Chairman of the Supervisory Board for the 2020 fiscal year
12.Approval of the compensation policy of the Supervisory Board members (except the Chairman of the Supervisory Board) for the 2020 fiscal year
13.Approval of the various components of overall compensation and benefits granted for the fiscal year ended 31 December 2019 to the corporate officers (mandataires sociaux)
14.Approval of the components of overall compensation and benefits granted for the fiscal year ended 31 December 2019 to the Chairman of the Executive Board
15.Approval of the components of overall compensation and benefits granted for the fiscal year ended 31 December 2019 to the Executive Board members (except the Chairman of the Executive Board)
16.Approval of the components of overall compensation and benefits granted for the fiscal year ended 31 December 2019 to the Chairman of the Supervisory Board
17.Authorization for the Company’s purchase of its own shares
Resolutions to be submitted to the extraordinary shareholder’s meeting:
18.Authorization granted to the Executive Board to allocate share subscription and/or share purchase options for the benefit of employees of the subsidiary of the Company, Innate Pharma Inc.
19.Authorization granted to the Executive Board to allocate existing or new free shares for the benefit of employed members of the Executive Committee, employed senior executives and/or corporate officers of the Company or its subsidiaries as part of their variable annual compensation
20.Authorization granted to the Executive Board to allocate existing or new free shares on the basis of the performance criteria for the benefit of executive officers, employed members of the Executive Committee, employed senior executives and/or corporate officers of the Company or its subsidiaries
21.Authorization granted to the Executive Board to allocate existing or new free shares on the basis of the performance criteria for the benefit of employees of the Company or its subsidiaries
22.Delegation of authority to the Executive Board for the purpose of issuing ordinary Company shares and/or of securities giving access to the share capital of the Company, with shareholders’ preferential subscription rights
23.Delegation of authority to the Executive Board for the purpose of issuing ordinary Company shares and/or of securities giving access to the share capital of the Company, without shareholders’ preferential subscription rights, through a public offering
24.Delegation of authority to the Executive Board for the purpose of issuing, without shareholders’ preferential subscription rights, ordinary shares of the Company and/or securities giving access to the share capital of the Company, through an offering referred to in paragraph 1° of Article L.411-2 of the French Monetary and Financial Code
25.Determination of the issuance price, up to the limit of 10% of the share capital per annum, of the ordinary shares and/or of securities giving access to the share capital of the Company, in the event of the suppression of shareholders’ preferential subscription rights
26.Delegation of authority to the Executive Board for the purpose of issuing of ordinary Company shares and /or of securities giving access to the share capital of the Company, without shareholders’ preferential subscription rights and reserved for certain categories of investors
27.Authorization granted to the Executive Board to increase of 15% the number of securities to be issued in the event of a share capital increase with or without shareholders’ preferential subscription rights
28.Delegation of authority to the Executive Board for the purpose of issuing ordinary shares and/or securities giving access to the share capital of the Company, as compensation for contributions in kind comprised of equity securities or securities giving access to the share capital
29.Delegation of authority to the Executive Board for the purpose of issuing ordinary shares and/or securities giving access to the share capital of the Company, in the event of a public exchange offer initiated by the Company
30.Overall cap applicable to the resolutions n° 22 to 24 and 26 to 29 above
31.Delegation of authority to the Executive Board for the purpose of issuing ordinary shares and/or securities giving access to the share capital of the Company for the benefit of the members of a company savings plan
32.Delegation of power granted to the Executive Board for the purpose of cancelling all or part of the treasury shares of the Company, acquired pursuant to the authorization to repurchase shares
33.Amendment to Article 15 IV. of the Articles of Association in order to change the quorum and majority for the deliberations of the Executive Board
34.Powers for formalities
|